View Older Stories View More Recent Stories

Mar 14, 2018 05:49PM Research from Bristol-Myers Squibb’s Innovative Oncology Development Program to Be Presented at AACR 2018 Demonstrates Commitment to Advancing Precision Medicine Research for Patients with Cancer
Mar 14, 2018 06:59AM Bristol-Myers Squibb to Announce Results for First Quarter 2018 on April 26
Mar 13, 2018 07:12AM GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance Cancer Care through Patient-Driven Insights
Mar 11, 2018 08:00AM Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants
Mar 7, 2018 04:15PM Bristol-Myers Squibb to Take Part in Barclays Global Healthcare Conference
Mar 6, 2018 07:00AM Bristol-Myers Squibb (BMY) Says Opdivo Now First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
Mar 6, 2018 06:59AM Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
Mar 5, 2018 06:59AM Bristol-Myers Squibb to Take Part in Cowen and Company 38th Annual Global Health Care Conference
Mar 1, 2018 04:20PM Bristol-Myers Squibb Announces Dividend Increase
Mar 1, 2018 04:15PM Bristol-Myers Squibb Names José Baselga, M.D., Ph.D. to Board of Directors
Feb 26, 2018 07:00AM Bristol-Myers Squibb Announces Expansion of the International Immuno-Oncology Network (II-ON) with Addition of Yale Cancer Center
Feb 14, 2018 07:03AM Bristol-Myers Squibb (BMY), Nektar Therapeutics (NKTR) to Partner on NKTR-214 in $1.85B+ Deal
Feb 14, 2018 06:59AM Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214
Feb 8, 2018 06:59AM Bristol-Myers Squibb to Take Part in Leerink 7th Annual Global Healthcare Conference
Feb 5, 2018 07:09AM Bristol-Myers Squibb (BMY) Reports Pivotal Phase 3 CheckMate-227 Study Provides Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination
Feb 5, 2018 06:59AM Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC)
Feb 5, 2018 06:59AM Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
Jan 25, 2018 04:15PM Five Prime Therapeutics (FPRX) Announces $25 Million Payment by Bristol-Myers Squibb (BMY) for Cabiralizumab Development Milestone
Jan 25, 2018 04:05PM Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
Jan 22, 2018 07:00AM Bristol-Myers Squibb (BMY) Reports EC Approval for its Yervoy for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Jan 22, 2018 06:59AM European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Jan 22, 2018 05:49AM Bristol-Myers Squibb (BMY) Reports Updated Data for Phase 2 CheckMate -142 Trial Evaluating Opdivo (nivolumab) and Yervoy (ipilimumab)
Jan 20, 2018 02:03PM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer
Jan 8, 2018 08:34AM Five Prime Therapeutics (FPRX) Secures $5M IND Milestone Payment from Bristol-Myers Squibb (BMY) Under Immune Checkpoint Pathways Discovery Collaboration; BMY to Extend Term for 2nd Time
Jan 8, 2018 08:30AM Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Col
Jan 3, 2018 09:00AM Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Dec 20, 2017 03:29PM Bristol-Myers Squibb (BMY) Announces FDA Approval for Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
Dec 20, 2017 03:28PM Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
Dec 20, 2017 07:00AM Bristol-Myers Squibb (BMY) Announces Clinical Trial Collaboration with TARIS Biomedical LLC
Dec 20, 2017 06:59AM TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration
Dec 19, 2017 09:00AM Bristol-Myers Squibb to Announce Results for Fourth Quarter 2017 on February 5th
Dec 18, 2017 07:00AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval of Yervoy for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Dec 18, 2017 06:59AM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Dec 14, 2017 05:44AM Bristol-Myers Squibb (BMY) Announces Exclusive Licensing Agreement with Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
Dec 13, 2017 06:30PM Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
Dec 13, 2017 05:29PM Bristol-Myers Squibb (BMY) Announces FDA Accepts its Application for Opdivo Plus Yervoy in Intermediate- and Poor-Risk Patients with Advanced RCC and Grants Priority Review
Dec 13, 2017 05:28PM U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Ca
Dec 11, 2017 10:31AM Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY) Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS and Opdivo in R/R Hodgkin Lymphoma
Dec 11, 2017 10:30AM Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refracto
Dec 9, 2017 09:30AM Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Dec 7, 2017 04:15PM Bristol-Myers Squibb Announces Dividend Increase
Dec 1, 2017 06:25AM Bristol-Myers Squibb (BMY) Says CheckMate -078 Phase 3 Opdivo Lung Cancer Trial with Predominantly Chinese Patients Stopped Early for Demonstrating Superior Overall Survival
Nov 30, 2017 07:00PM CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival
Nov 30, 2017 04:59PM Bristol-Myers Squibb to Take Part at the Citi 2017 Global Healthcare Conference
Nov 29, 2017 04:23PM Bristol-Myers Squibb (BMY) Announces 33 Presentations at ASH
Nov 29, 2017 04:15PM Bristol-Myers Squibb to Present New Data Across a Broad Range of Blood Cancers at the 59th Annual Meeting & Exposition of the American Society of Hematology
Nov 28, 2017 06:59AM Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Neutrolis, Remora Therapeutics
Nov 28, 2017 06:41AM Bristol-Myers Squibb (BMY) Says EMA Validated its Type II Variation Application for Opdivo Plus Yervoy in Intermediate- and Poor-Risk Patients with Advanced RCC
Nov 28, 2017 06:40AM European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal C
Nov 22, 2017 06:59AM Bristol-Myers Squibb to Take Part in Evercore ISI Biopharma Conference
View More Recent Stories View Older Stories